The present disclosure relates generally to antimicrobial floor coatings and formulations. More particularly, the various embodiments described herein relate to antimicrobial floor coatings and formulations having polymeric material and antimicrobial copper ions.
Floor coatings and floor paints are important for aesthetics and wear resistance of underlying concrete, wood and other flooring materials. These floor coatings and paints can be prone to contamination from microorganisms (e.g., bacteria, fungi, viruses, and the like), particularly as compared to coatings and paints employed on other surfaces (e.g., walls). Yet floor coatings and paints are also required to exhibit higher durability and wear resistance than their counterparts employed on other surfaces, such as walls.
While there are a few floor coatings presently on the market that claim to have antimicrobial properties, none of these coatings demonstrate antimicrobial efficacy under the rigorous antimicrobial standards set forth by the U.S. Environmental Protection Agency (“EPA”). Rather, it is believed that these conventional antimicrobial coatings exhibit antimicrobial performance as judged by a test protocol, such as the Japanese Industrial Standard JISZ 2801 test, that provides for antimicrobial contact under wet conditions. In particular, these protocols promote interactions between the antimicrobial agents in the coatings and the microorganisms on the wet or moist test surface over a 24 hour period. In contrast, EPA-derived antimicrobial test protocols are significantly more rigorous and more realistic given that they require ‘dry’ test surfaces and a quicker kill over a 2 hour period.
Accordingly, there is a need for antimicrobial floor coatings and formulations that offer wear resistance and antimicrobial efficacy under ‘wet’ test conditions. The required degree of antimicrobial efficacy can include the demonstration of a 2 log reduction in a concentration of Staphylococcus aureus (S. aureus), as determined under a test procedure derived from a protocol of the United States Environmental Protection Agency (the “Modified EPA Copper Test Protocol”). As S. aureus is one of the key bacteria against which a kill must be demonstrated by the Modified EPA Copper Test Protocol, a kill of S. aureus may be considered reasonable evidence of efficacy against a broad range of other bacteria (e.g., Eschecheria coli, Pseudomonas aeruginosa, and Enterobacter aerogenes).
A first aspect of the present disclosure pertains to an antimicrobial floor coating that includes a matrix comprising a polymeric material; and a plurality of second phase particles comprising a controlled release agent, the controlled release agent comprising a plurality of antimicrobial copper ions. The polymeric material comprises an epoxy and an acrylic, and the plurality of second phase particles is distributed within the matrix. Further, an exterior surface of the coating exhibits at least a 2 log reduction in a concentration of Staphylococcus aureus under a Modified EPA Copper Test Protocol. In embodiments, the exterior surface of the coating can exhibit at least a 3 log reduction in a concentration of Staphylococcus aureus under a Modified EPA Copper Test Protocol.
In implementations of the first aspect, the controlled release agent can further comprise a phase-separable glass. The floor coating can further comprise one or more pigments. The plurality of antimicrobial copper ions can be at a concentration of about 2 wt. % or less in the coating.
In some implementations of these floor coatings, the phase-separable glass can comprise at least one of B2O3, P2O5 and R2O, and the plurality of antimicrobial ions is cuprite comprising a plurality of Cu+ ions. The phase-separable glass can also comprise: SiO2 in the range from about 40 to about 70 mol %, Al2O3 in the range from about 0 to about 20 mol %, Cu-containing oxide in the range from about 10 to about 50 mol %, CaO in the range from about 0 to about 15 mol %, MgO in the range from about 0 to about 15 mol %, P2O5 in the range from about 0 to about 25 mol %, B2O3 in the range from about 0 to about 25 mol %, K2O in the range from about 0 to about 20 mol %, ZnO in the range from about 0 to about 5 mol %, Na2O in the range from about 0 to about 20 mol %, Fe2O3 in the range from about 0 to about 5 mol %, and an optional nucleating agent comprising either one or both of TiO2 and ZrO2, wherein the amount of the Cu-containing oxide is greater than the amount of Al2O3.
In further implementations of these floor coatings, the polymeric material is derived from a no-mix, one-part epoxy acrylic floor paint. The phase-separable glass can comprise: about 45 mol % SiO2, about 35 mol % CuO, about 7.5 mol % K2O, about 7.5 mol % B2O3 and about 5 mol % P2O5. Further, the epoxy can be derived from an epoxy precursor that comprises one or more of dipropylene glycol monomethyl ether, dipropylene glycol butoxy ether, and ethylene glycol, the acrylic can comprise a styrene acrylic polymer, and the matrix can further comprise nepheline syenite.
A further aspect of the present disclosure pertains to an antimicrobial floor coating formulation that includes an epoxy; an acrylic polymer; an aqueous medium; and a plurality of second phase particles comprising a controlled release agent, the controlled release agent comprising a plurality of antimicrobial copper ions. Further, the plurality of second phase particles is at a concentration that ranges from about 25 g/gal to about 150 g/gal of the formulation. In embodiments, the plurality of second phase particles is at a concentration that ranges from about 50 g/gal to about 125 g/gal of the formulation. In further implementations of this aspect, an exterior surface of the formulation upon drying of the aqueous medium exhibits at least a 2 log reduction in a concentration of Staphylococcus aureus under a Modified EPA Copper Test Protocol.
According to aspects of these formulations, the controlled release agent can further comprise a phase-separable glass. The floor coating formulation can further comprise one or more pigments.
In some implementations of these floor coating formulations, the phase-separable glass can comprise at least one of B2O3, P2O5 and R2O, and the plurality of antimicrobial ions is cuprite comprising a plurality of Cu+ ions. The phase-separable glass can also comprise: SiO2 in the range from about 40 to about 70 mol %, Al2O3 in the range from about 0 to about 20 mol %, Cu-containing oxide in the range from about 10 to about 50 mol %, CaO in the range from about 0 to about 15 mol %, MgO in the range from about 0 to about 15 mol %, P2O5 in the range from about 0 to about 25 mol %, B2O3 in the range from about 0 to about 25 mol %, K2O in the range from about 0 to about 20 mol %, ZnO in the range from about 0 to about 5 mol %, Na2O in the range from about 0 to about 20 mol %, Fe2O3 in the range from about 0 to about 5 mol %, and an optional nucleating agent comprising either one or both of TiO2 and ZrO2, wherein the amount of the Cu-containing oxide is greater than the amount of Al2O3.
In further implementations of these floor coating formulations, the epoxy, the acrylic polymer and the aqueous medium are derived from a no-mix, one-part epoxy acrylic floor paint. The phase-separable glass can comprise: about 45 mol % SiO2, about 35 mol % CuO, about 7.5 mol % K2O, about 7.5 mol % B2O3 and about 5 mol % P2O5. Further, the epoxy can be derived from an epoxy precursor that comprises one or more of dipropylene glycol monomethyl ether, dipropylene glycol butoxy ether, and ethylene glycol, the acrylic can comprise a styrene acrylic polymer, and the matrix can further comprise nepheline syenite.
Additional features and advantages will be set forth in the detailed description which follows, and in part will be readily apparent to those skilled in the art from that description or recognized by practicing the embodiments as described herein, including the detailed description which follows, the claims, as well as the appended drawings.
It is to be understood that both the foregoing general description and the following detailed description are merely exemplary, and are intended to provide an overview or framework to understanding the nature and character of the claims. The accompanying drawings are included to provide a further understanding, and are incorporated in and constitute a part of this specification. The drawings illustrate one or more embodiment(s), and together with the description serve to explain principles and operation of the various embodiments.
Reference will now be made in detail to various embodiment(s), examples of which are illustrated in the accompanying drawings.
Aspects of the disclosure generally pertain to antimicrobial floor coatings and formulations. More particularly, the various embodiments described herein relate to antimicrobial floor coatings and formulations having polymeric material that comprises an epoxy and an acrylic, along with antimicrobial copper ions. In preferred implementations, the polymeric material is derived from a no-mix, one-part epoxy acrylic floor paint. These antimicrobial floor coatings have an unexpected combination of high durability, indicative of floor coatings, and antimicrobial efficacy will kills of >99% of human pathogens under the Modified EPA Copper Test Protocol. The antimicrobial properties of the floor coatings and floor coating formulations disclosed herein include antiviral and/or antibacterial properties. As used herein the term “antimicrobial,” means a material, or a surface of a material that will kill or inhibit the growth of bacteria, viruses, and/or fungi. The term as used herein does not mean the material or the surface of the material will kill or inhibit the growth of all species of microbes within such families, but that it will kill or inhibit the growth or one or more species of microbes from such families.
As used herein the term “log reduction” means −log (Ca/C0), where Ca=the colony form unit (CFU) number of the antimicrobial surface and C0=the colony form unit (CFU) of the control surface that is not an antimicrobial surface. As an example, a “3 log” reduction equals about 99.9% of the bacteria, viruses, and/or fungi killed.
Referring to
Note that the coating 100 is depicted in
Referring again to
As outlined earlier, the second phase particles 20 of the antimicrobial floor coating 100 comprise a controlled release agent, which may include a phase-separable glass with a copper-containing antimicrobial agent. The phase-separable glass employed in the particles 20 is described in U.S. patent application Ser. No. 14/623,077, filed on Feb. 16, 2015, now issued as U.S. Pat. No. 9,622,483, the salient portions of which related to phase-separable glass are hereby incorporated by reference within this disclosure. In one or more embodiments, the phase-separable glasses employed in the second phase particles 20 include a Cu species. In one or more alternative embodiments, the Cu species may include Cu1+, Cu0, and/or Cu2+. The combined total of the Cu species may be about 10 wt. % or more. However, as will be discussed in more detail below, the amount of Cu1+ is minimized or is reduced such that the antimicrobial glass is substantially free of Cu2+. The Cu1+ ions may be present on or in the surface and/or the bulk of the antimicrobial glass. In some embodiments, the Cu1+ ions are present in the glass network and/or the glass matrix of the antimicrobial glass. Where the Cu1+ ions are present in the glass network, the Cu1+ ions are atomically bonded to the atoms in the glass network. Where the Cu1+ ions are present in the glass matrix, the Cu1+ ions may be present in the form of Cu1+ crystals that are dispersed in the glass matrix. In some embodiments the Cu1+ crystals include cuprite (Cu2O). In such embodiments, where Cu1+ crystals are present, the material may be referred to as an antimicrobial glass ceramic, which is intended to refer to a specific type of glass with crystals that may or may not be subjected to a traditional ceramming process by which one or more crystalline phases are introduced and/or generated in the glass. Where the Cu1+ ions are present in a non-crystalline form, the material may be referred to as an antimicrobial glass. In some embodiments, both Cu1+ crystals and Cu1+ ions not associated with a crystal are present in the antimicrobial glasses described herein.
In further embodiments, the second phase particles 20 can comprise other controlled release agents (i.e., agents other than a phase-separable glass) that comprise a copper-containing antimicrobial agent. These other controlled release agents can include, but are not limited to, inorganic species like zeolites, organic species like micelles and amphiphilic compounds, hydrogels, caged compounds like cyclodextrins, other encapsulating polymers, and hybrid/nanoparticle species such as core-shell particles (e.g., a cuprite core-silica shell). Further, in some implementations, the controlled release agent can comprise a phase-separable glass and any one or more of these other controlled release agents.
In one or more aspects of the antimicrobial floor coating 100, the antimicrobial glass employed in the second phase particles 20 may be formed from a composition that can include, in mole percent, SiO2 in the range from about 40 to about 70, Al2O3 in the range from about 0 to about 20, a copper-containing oxide in the range from about 10 to about 30, CaO in the range from about 0 to about 15, MgO in the range from about 0 to about 15, P2O5 in the range from about 0 to about 25, B2O3 in the range from about 0 to about 25, K2O in the range from about 0 to about 20, ZnO in the range from about 0 to about 5, Na2O in the range from about 0 to about 20, and/or Fe2O3 in the range from about 0 to about 5. In such embodiments, the amount of the copper-containing oxide is greater than the amount of Al2O3. In some embodiments, the composition may include a content of R2O, where R may include K, Na, Li, Rb, Cs, and combinations thereof.
According to another aspect of the antimicrobial floor coating 100, the phase-separable glass, as or part of the controlled release agent, can comprise at least one of B2O3, P2O5 and R2O, and the plurality of antimicrobial ions is cuprite comprising a plurality of Cu+ ions. The phase-separable glass can also comprise: SiO2 in the range from about 40 to about 70 mol %, Al2O3 in the range from about 0 to about 20 mol %, Cu-containing oxide in the range from about 10 to about 50 mol %, CaO in the range from about 0 to about 15 mol %, MgO in the range from about 0 to about 15 mol %, P2O5 in the range from about 0 to about 25 mol %, B2O3 in the range from about 0 to about 25 mol %, K2O in the range from about 0 to about 20 mol %, ZnO in the range from about 0 to about 5 mol %, Na2O in the range from about 0 to about 20 mol %, Fe2O3 in the range from about 0 to about 5 mol %, and an optional nucleating agent comprising either one or both of TiO2 and ZrO2, wherein the amount of the Cu-containing oxide is greater than the amount of Al2O3. According to a preferred implementation, the phase-separable glass can comprise: about 45 mol % SiO2, about 35 mol % CuO, about 7.5 mol % K2O, about 7.5 mol % B2O3 and about 5 mol % P2O5 (“Cu-Glass” or “Cu glass”).
In the embodiments of the compositions described herein, SiO2 serves as the primary glass-forming oxide. The amount of SiO2 present in a composition should be enough to provide glasses that exhibit the requisite chemical durability suitable for its use or application within the antimicrobial floor coating 100. The upper limit of SiO2 may be selected to control the melting temperature of the compositions described herein. For example, excess SiO2 could drive the melting temperature at 200 poise to high temperatures at which defects such as fining bubbles may appear or be generated during processing and in the resulting glass. Furthermore, compared to most oxides, SiO2 decreases the compressive stress created by an ion exchange process of the resulting glass. In other words, glass formed from compositions with excess SiO2 may not be ion-exchangeable to the same degree as glass formed from compositions without excess SiO2. Additionally or alternatively, SiO2 present in the compositions according to one or more embodiments could increase the plastic deformation prior break properties of the resulting glass. An increased SiO2 content in the glass formed from the compositions described herein may also increase the indentation fracture threshold of the glass.
In one or more aspects of the antimicrobial floor coating 100, the composition of the controlled release agent, in the form of a phase-separable glass, includes SiO2 in an amount, in mole percent, in the range from about 40 to about 70, from about 40 to about 69, from about 40 to about 68, from about 40 to about 67, from about 40 to about 66, from about 40 to about 65, from about 40 to about 64, from about 40 to about 63, from about 40 to about 62, from about 40 to about 61, from about 40 to about 60, from about 41 to about 70, from about 42 to about 70, from about 43 to about 70, from about 44 to about 70, from about 45 to about 70, from about 46 to about 70, from about 47 to about 70, from about 48 to about 70, from about 49 to about 70, from about 50 to about 70, from about 41 to about 69, from about 42 to about 68, from about 43 to about 67 from about 44 to about 66 from about 45 to about 65, from about 46 to about 64, from about 47 to about 63, from about 48 to about 62, from about 49 to about 61, from about 50 to about 60, and all ranges and sub-ranges therebetween.
In one or more aspects of the antimicrobial floor coating 100, the composition of the controlled release agent, in the form of phase-separable glass, includes Al2O3 in an amount, in mole percent, in the range from about 0 to about 20, from about 0 to about 19, from about 0 to about 18, from about 0 to about 17, from about 0 to about 16, from about 0 to about 15, from about 0 to about 14, from about 0 to about 13, from about 0 to about 12, from about 0 to about 11 from about 0 to about 10, from about 0 to about 9, from about 0 to about 8, from about 0 to about 7, from about 0 to about 6, from about 0 to about 5, from about 0 to about 4, from about 0 to about 3, from about 0 to about 2, from about 0 to about 1, from about 0.1 to about 1, from about 0.2 to about 1, from about 0.3 to about 1 from about 0.4 to about 1 from about 0.5 to about 1, from about 0 to about 0.5, from about 0 to about 0.4, from about 0 to about 0.3 from about 0 to about 0.2, from about 0 to about 0.1, and all ranges and sub-ranges therebetween. In some embodiments, the composition is substantially free of Al2O3. As used herein, the phrase “substantially free”, with respect to the components of the composition and/or resulting glass, means that the component is not actively or intentionally added to the compositions during initial batching or subsequent post processing (e.g., ion exchange process), but may be present as an impurity. For example, a composition, a glass may be describe as being substantially free of a component, when the component is present in an amount of less than about 0.01 mol %.
The amount of Al2O3 may be adjusted to serve as a glass-forming oxide and/or to control the viscosity of molten compositions within the phase-separable glass, as employed as the controlled release agent of the second phase particles 20. Without being bound by theory, it is believed that when the concentration of alkali oxide (R2O) in a composition is equal to or greater than the concentration of Al2O3, the aluminum ions are found in tetrahedral coordination with the alkali ions acting as charge-balancers. This tetrahedral coordination greatly enhances various post-processing (e.g., ion exchange process) of glasses formed from such compositions. Divalent cation oxides (RO) can also charge balance tetrahedral aluminum to various extents. While elements such as calcium, zinc, strontium, and barium behave equivalently to two alkali ions, the high field strength of magnesium ions causes them to not fully charge balance aluminum in tetrahedral coordination, resulting in the formation of five- and six-fold coordinated aluminum. Generally, Al2O3 can play an important role in ion-exchangeable compositions and strengthened glasses since it enables a strong network backbone (i.e., high strain point) while allowing for the relatively fast diffusivity of alkali ions. However, when the concentration of Al2O3 is too high, the composition may exhibit lower liquidus viscosity and, thus, Al2O3 concentration may be controlled within a reasonable range. Moreover, as will be discussed in more detail below, excess Al2O3 has been found to promote the formation of Cu2+ ions, instead of the desired Cu1+ ions.
In one or more aspects of the antimicrobial floor coating 100, the composition of the phase-separable glass, as employed as the controlled release agent of the second phase particles 20, includes a copper-containing oxide in an amount, in mole percent, in the range from about 10 to about 50, from about 10 to about 49, from about 10 to about 48, from about 10 to about 47, from about 10 to about 46, from about 10 to about 45, from about 10 to about 44, from about 10 to about 43, from about 10 to about 42, from about 10 to about 41, from about 10 to about 40, from about 10 to about 39, from about 10 to about 38, from about 10 to about 37, from about 10 to about 36, from about 10 to about 35, from about 10 to about 34, from about 10 to about 33, from about 10 to about 32, from about 10 to about 31, from about 10 to about 30, from about 10 to about 29, from about 10 to about 28, from about 10 to about 27, from about 10 to about 26, from about 10 to about 25, from about 10 to about 24, from about 10 to about 23, from about 10 to about 22, from about 10 to about 21, from about 10 to about 20, from about 11 to about 50, from about 12 to about 50, from about 13 to about 50, from about 14 to about 50, from about 15 to about 50, from about 16 to about 50, from about 17 to about 50, from about 18 to about 50, from about 19 to about 50, from about 20 to about 50, from about 10 to about 30, from about 11 to about 29, from about 12 to about 28, from about 13 to about 27, from about 14 to about 26, from about 15 to about 25, from about 16 to about 24, from about 17 to about 23, from about 18 to about 22, from about 19 to about 21, and all ranges and sub-ranges therebetween. In one or more specific embodiments, the copper-containing oxide may be present in the composition in an amount of about 20 mol %, about 25 mol %, about 30 mol % or about 35 mol %. The copper-containing oxide may include CuO, Cu2O and/or combinations thereof. Further, in some embodiments of the antimicrobial floor coating 100, the antimicrobial copper ions in the controlled release agent can be at a concentration of about 2 wt. % or less in the coating, e.g., at about 2 wt. %, about 1.9 wt. %, about 1.8 wt. %, about 1.7 wt. %, about 1.6 wt. %, about 1.5 wt. %, about 1.4 wt. %, about 1.3 wt. %, about 1.2 wt. %, about 1.1 wt. %, about 1.0 wt. %, about 0.9 wt. %, about 0.8 wt. %, about 0.7 wt. %, about 0.6 wt. %, about 0.5 wt. %, about 0.4 wt. %, about 0.3 wt. %, about 0.2 wt. %, about 0.1 wt. %, and all concentrations between these values.
The copper-containing oxides in the composition form the Cu1+ ions present in the resulting glass. Copper may be present in the composition and/or the glasses including the composition in various forms including Cu0, Cu1+, and Cu2+. Copper in the Cu0 or Cu1+ forms provide antimicrobial activity. However forming and maintaining these states of antimicrobial copper are difficult and often, in known compositions, Cu2+ ions are formed instead of the desired Cu0 or Cu1+ ions.
In one or more aspects of the antimicrobial floor coating 100, the amount of copper-containing oxide in a phase-separable glass, as employed as the controlled release agent of the second phase particles 20, is greater than the amount of Al2O3 in the composition. Without being bound by theory, it is believed that an about equal amount of copper-containing oxides and Al2O3 in the composition results in the formation of tenorite (CuO) instead of cuprite (Cu2O). The presence of tenorite decreases the amount of Cu1+ in favor of Cu2+ and thus leads to reduced antimicrobial activity. Moreover, when the amount of copper-containing oxides is about equal to the amount of Al2O3, aluminum prefers to be in a four-fold coordination and the copper in the composition and resulting glass remains in the Cu2+ form so that the charge remains balanced. Where the amount of copper-containing oxide exceeds the amount of Al2O3, then it is believed that at least a portion of the copper is free to remain in the Cu1+ state, instead of the Cu1+ state, and thus the presence of Cu1+ ions increases.
In one or more aspects of the antimicrobial floor coating 100, the composition of one or more embodiments of the phase-separable glass, as employed as the controlled release agent of the second phase particles 20, includes P2O5 in an amount, in mole percent, in the range from about 0 to about 25, from about 0 to about 22, from about 0 to about 20, from about 0 to about 18, from about 0 to about 16, from about 0 to about 15, from about 0 to about 14, from about 0 to about 13, from about 0 to about 12, from about 0 to about 11, from about 0 to about 10, from about 0 to about 9, from about 0 to about 8, from about 0 to about 7, from about 0 to about 6, from about 0 to about 5, from about 0 to about 4, from about 0 to about 3, from about 0 to about 2, from about 0 to about 1, from about 0.1 to about 1, from about 0.2 to about 1, from about 0.3 to about 1 from about 0.4 to about 1 from about 0.5 to about 1, from about 0 to about 0.5, from about 0 to about 0.4, from about 0 to about 0.3 from about 0 to about 0.2, from about 0 to about 0.1, and all ranges and sub-ranges therebetween. In some embodiments, the composition includes about 10 mol % or about 5 mol % P2O5 or, alternatively, may be substantially free of P2O5.
In one or more embodiments, P2O5 forms at least part of a less durable phase or a degradable phase in the phase-separable glass, as employed as the controlled release agent of the second phase particles 20, of the antimicrobial floor coating 100. The relationship between the degradable phase(s) of the glass and antimicrobial activity is discussed in greater detail herein. In one or more embodiments, the amount of P2O5 may be adjusted to control crystallization of the composition and/or glass during forming. For example, when the amount of P2O5 is limited to about 5 mol % or less or even 10 mol % or less, crystallization may be minimized or controlled to be uniform. However, in some embodiments, the amount or uniformity of crystallization of the composition and/or glass may not be of concern and thus, the amount of P2O5 utilized in the composition may be greater than 10 mol %.
In one or more embodiments, the amount of P2O5 in the composition may be adjusted based on the desired damage resistance of the phase-separable glass, as employed as the controlled release agent of the second phase particles 20, of the antimicrobial floor coating 100, despite the tendency for P2O5 to form a less durable phase or a degradable phase in the glass. Without being bound by theory, P2O5 can decrease the melting viscosity relative to SiO2. In some instances, P2O5 is believed to help to suppress zircon breakdown viscosity (i.e., the viscosity at which zircon breaks down to form ZrO2) and may be more effective in this regard than SiO2. When glass is to be chemically strengthened via an ion exchange process, P2O5 can improve the diffusivity and decrease ion exchange times, when compared to other components that are sometimes characterized as network formers (e.g., SiO2 and/or B2O3).
In one or more aspects of the antimicrobial floor coating 100, the composition of one or more embodiments of the phase-separable glass, as employed as the controlled release agent of the second phase particles 20, includes B2O3 in an amount, in mole percent, in the range from about 0 to about 25, from about 0 to about 22, from about 0 to about 20, from about 0 to about 18, from about 0 to about 16, from about 0 to about 15, from about 0 to about 14, from about 0 to about 13, from about 0 to about 12, from about 0 to about 11, from about 0 to about 10, from about 0 to about 9, from about 0 to about 8, from about 0 to about 7, from about 0 to about 6, from about 0 to about 5, from about 0 to about 4, from about 0 to about 3, from about 0 to about 2, from about 0 to about 1, from about 0.1 to about 1, from about 0.2 to about 1, from about 0.3 to about 1 from about 0.4 to about 1 from about 0.5 to about 1, from about 0 to about 0.5, from about 0 to about 0.4, from about 0 to about 0.3 from about 0 to about 0.2, from about 0 to about 0.1, and all ranges and sub-ranges therebetween. In some embodiments, the composition includes a non-zero amount of B2O3, which may be, for example, about 10 mol % or about 5 mol %. The composition of some embodiments may be substantially free of B2O3.
In one or more embodiments, B2O3 forms a less durable phase or a degradable phase in the phase-separable glass, as employed as the controlled release agent of the second phase particles 20, of the antimicrobial floor coating 100. The relationship between the degradable phase(s) of the glass and antimicrobial activity is discussed in greater detail herein. Without being bound by theory, it is believed the inclusion of B2O3 in compositions imparts damage resistance in glasses incorporating such compositions, despite the tendency for B2O3 to form a less durable phase or a degradable phase in the glass. The composition of one or more embodiments includes one or more alkali oxides (R2O) (e.g., Li2O, Na2O, K2O, Rb2O, and/or Cs2O). In some embodiments, the alkali oxides modify the melting temperature and/or liquidus temperatures of such compositions. In one or more embodiments, the amount of alkali oxides may be adjusted to provide a composition exhibiting a low melting temperature and/or a low liquidus temperature. Without being bound by theory, the addition of alkali oxide(s) may increase the coefficient of thermal expansion (CTE) and/or lower the chemical durability of the antimicrobial glasses that include such compositions. In some cases these attributes may be altered dramatically by the addition of alkali oxide(s).
In one or more aspects of the antimicrobial floor coating 100, the composition of one or more embodiments of the phase-separable glass, as employed as the controlled release agent of the second phase particles 20, may include one or more divalent cation oxides, such as alkaline earth oxides and/or ZnO. Such divalent cation oxides may be included to improve the melting behavior of the compositions.
In one or more aspects of the antimicrobial floor coating 100, the composition of one or more embodiments of the phase-separable glass, as employed as the controlled release agent of the second phase particles 20, may include CaO in an amount, in mole percent, in the range from about 0 to about 15, from about 0 to about 14, from about 0 to about 13, from about 0 to about 12, from about 0 to about 11, from about 0 to about 10, from about 0 to about 9, from about 0 to about 8, from about 0 to about 7, from about 0 to about 6, from about 0 to about 5, from about 0 to about 4, from about 0 to about 3, from about 0 to about 2, from about 0 to about 1, from about 0.1 to about 1, from about 0.2 to about 1, from about 0.3 to about 1 from about 0.4 to about 1 from about 0.5 to about 1, from about 0 to about 0.5, from about 0 to about 0.4, from about 0 to about 0.3 from about 0 to about 0.2, from about 0 to about 0.1, and all ranges and sub-ranges therebetween. In some embodiments, the composition is substantially free of CaO.
In one or more aspects of the antimicrobial floor coating 100, the composition of one or more embodiments of the phase-separable glass, as employed as the controlled release agent of the second phase particles 20, may include MgO in an amount, in mole percent, in the range from about 0 to about 15, from about 0 to about 14, from about 0 to about 13, from about 0 to about 12, from about 0 to about 11, from about 0 to about 10, from about 0 to about 9, from about 0 to about 8, from about 0 to about 7, from about 0 to about 6, from about 0 to about 5, from about 0 to about 4, from about 0 to about 3, from about 0 to about 2, from about 0 to about 1, from about 0.1 to about 1, from about 0.2 to about 1, from about 0.3 to about 1 from about 0.4 to about 1 from about 0.5 to about 1, from about 0 to about 0.5, from about 0 to about 0.4, from about 0 to about 0.3 from about 0 to about 0.2, from about 0 to about 0.1, and all ranges and sub-ranges therebetween. In some embodiments, the composition is substantially free of MgO.
In one or more aspects of the antimicrobial floor coating 100, the composition of one or more embodiments of the phase-separable glass, as employed as the controlled release agent of the second phase particles 20, may include ZnO in an amount, in mole percent, in the range from about 0 to about 5, from about 0 to about 4, from about 0 to about 3, from about 0 to about 2, from about 0 to about 1, from about 0.1 to about 1, from about 0.2 to about 1, from about 0.3 to about 1 from about 0.4 to about 1 from about 0.5 to about 1, from about 0 to about 0.5, from about 0 to about 0.4, from about 0 to about 0.3 from about 0 to about 0.2, from about 0 to about 0.1, and all ranges and sub-ranges therebetween. In some embodiments, the composition is substantially free of ZnO.
In one or more aspects of the antimicrobial floor coating 100, the composition of one or more embodiments of the phase-separable glass, as employed as the controlled release agent of the second phase particles 20, may include Fe2O3, in mole percent, in the range from about 0 to about 5, from about 0 to about 4, from about 0 to about 3, from about 0 to about 2, from about 0 to about 1, from about 0.1 to about 1, from about 0.2 to about 1, from about 0.3 to about 1 from about 0.4 to about 1 from about 0.5 to about 1, from about 0 to about 0.5, from about 0 to about 0.4, from about 0 to about 0.3 from about 0 to about 0.2, from about 0 to about 0.1, and all ranges and sub-ranges therebetween. In some embodiments, the composition is substantially free of Fe2O3.
In one or more aspects of the antimicrobial floor coating 100, the composition of one or more embodiments of the phase-separable glass, as employed as the controlled release agent of the second phase particles 20, may include one or more colorants, e.g., additives, pigments or the like that imbue color in the coating 100. Examples of such colorants include NiO, TiO2, Fe2O3, Cr2O3, Co3O4 and other known colorants and pigments. In some embodiments, the one or more colorants may be present in an amount in the range up to about 10 mol %. In some instances, the one or more colorants may be present in an amount in the range from about 0.01 mol % to about 10 mol %, from about 1 mol % to about 10 mol %, from about 2 mol % to about 10 mol %, from about 5 mol % to about 10 mol %, from about 0.01 mol % to about 8 mol %, or from about 0.01 mol % to about 5 mol %. In some aspects, the colorant employed in the second phase particles 20 is selected to match the color of the matrix employed in the antimicrobial floor coating 100.
In one or more aspects of the antimicrobial floor coating 100, the composition of one or more embodiments of the phase-separable glass, as employed as the controlled release agent of the second phase particles 20, may include one or more nucleating agents. Exemplary nucleating agents include TiO2, ZrO2 and other known nucleating agents in the art. The composition can include one or more different nucleating agents. The nucleating agent content of the composition may be in the range from about 0.01 mol % to about 1 mol %. In some instances, the nucleating agent content may be in the range from about 0.01 mol % to about 0.9 mol %, from about 0.01 mol % to about 0.8 mol %, from about 0.01 mol % to about 0.7 mol %, from about 0.01 mol % to about 0.6 mol %, from about 0.01 mol % to about 0.5 mol %, from about 0.05 mol % to about 1 mol %, from about 0.1 mol % to about 1 mol %, from about 0.2 mol % to about 1 mol %, from about 0.3 mol % to about 1 mol %, or from about 0.4 mol % to about 1 mol %, and all ranges and sub-ranges therebetween.
The phase-separable glasses of the foregoing compositions, as employed as the controlled release agent of the second phase particles 20, of the antimicrobial floor coating 100, may include a plurality of Cu1+ ions. In some embodiments, such Cu1+ ions form part of the glass network and may be characterized as a glass modifier. Without being bound by theory, where Cu1+ ions are part of the glass network, it is believed that during typical glass formation processes, the cooling step of the molten glass occurs too rapidly to allow crystallization of the copper-containing oxide (e.g., CuO and/or Cu2O). Thus the Cu1+ remains in an amorphous state and becomes part of the glass network. In some cases, the total amount of Cu1+ ions, whether they are in a crystalline phase or in the glass matrix, may be even higher, such as up to 40 mol %, up to 50 mol %, or up to 60 mol %.
In one or more embodiments, the phase-separable glasses formed from the compositions disclosed herein, as employed as the controlled release agent of the second phase particles 20 of the antimicrobial floor coating 100, include Cu1+ ions that are dispersed in the glass matrix as Cu1+ crystals. In one or more embodiments, the Cu1+ crystals may be present in the form of cuprite. The cuprite present in the glass may form a phase that is distinct from the glass matrix or glass phase. In other embodiments, the cuprite may form part of or may be associated with one or more glasses phases (e.g., the durable phase described herein). The Cu1+ crystals may have an average major dimension of about 5 micrometers (μm) or less, about 4 micrometers (μm) or less, about 3 micrometers (μm) or less, about 2 micrometers (μm) or less, about 1.9 micrometers (μm) or less, about 1.8 micrometers (μm) or less, about 1.7 micrometers (μm) or less, about 1.6 micrometers (μm) or less, about 1.5 micrometers (μm) or less, about 1.4 micrometers (μm) or less, about 1.3 micrometers (μm) or less, about 1.2 micrometers (μm) or less, about 1.1 micrometers or less, about 1 micrometers or less, about 0.9 micrometers (μm) or less, about 0.8 micrometers (μm) or less, about 0.7 micrometers (μm) or less, about 0.6 micrometers (μm) or less, about 0.5 micrometers (μm) or less, about 0.4 micrometers (μm) or less, about 0.3 micrometers (μm) or less, about 0.2 micrometers (μm) or less, about 0.1 micrometers (μm) or less, about 0.05 micrometers (μm) or less, and all ranges and sub-ranges therebetween. As used herein and with respect to the phrase “average major dimension”, the word “average” refers to a mean value and the word “major dimension” is the greatest dimension of the particle as measured by scanning electron microscopy (SEM). In some embodiments, the cuprite phase may be present in the glass of the second phase particles 20 of the antimicrobial composite article 100 in an amount of at least about 10 wt. %, at least about 15 wt. %, at least about 20 wt. %, at least about 25 wt. %, and all ranges and subranges therebetween of the antimicrobial glass. In certain implementations, the phase-separable glasses formed from the compositions disclosed herein, as employed as the controlled release agent of the second phase particles 20 of the antimicrobial floor coating 100, can include 10 to 50 mol % cuprite, and all ranges and subranges therebetween, of the phase-separable glass.
In some embodiments, the phase-separable glasses, as employed as the controlled release agent of the second phase particles 20, of the antimicrobial floor coating 100 may include about 70 wt. % Cu1+ or more and about 30 wt. % of Cu1+ or less. The Cu1+ ions may be present in tenorite form and/or even in the glass (i.e., not as a crystalline phase).
In some embodiments, the total amount of Cu by wt. % in the phase-separable glasses, as employed as the controlled release agent of the second phase particles 20, of the antimicrobial floor coating 100 may be in the range from about 10 to about 30, from about 15 to about 25, from about 11 to about 30, from about 12 to about 30, from about 13 to about 30, from about 14 to about 30, from about 15 to about 30, from about 16 to about 30, from about 17 to about 30, from about 18 to about 30, from about 19 to about 30, from about 20 to about 30, from about 10 to about 29, from about 10 to about 28, from about 10 to about 27, from about 10 to about 26, from about 10 to about 25, from about 10 to about 24, from about 10 to about 23, from about 10 to about 22, from about 10 to about 21, from about 10 to about 20, from about 16 to about 24, from about 17 to about 23, from about 18 to about 22, from about 19 to about 21, and all ranges and sub-ranges therebetween. In one or more embodiments, the ratio of Cu1+ ions to the total amount Cu in the glass is about 0.5 or greater, 0.55 or greater, 0.6 or greater, 0.65 or greater, 0.7 or greater, 0.75 or greater, 0.8 or greater, 0.85 or greater, 0.9 or greater, or even 1 or greater, and all ranges and sub-ranges therebetween. The amount of Cu and the ratio of Cu1+ ions to total Cu may be determined by inductively coupled plasma (ICP) techniques known in the art.
In some embodiments, the phase-separable glass, as employed as the controlled release agent of the second phase particles 20, of the antimicrobial floor coating 100 may exhibit a greater amount of Cu1+ and/or Cu0 than Cu2+. For example, based on the total amount of Cu1+, Cu2+, and Cu0 in the glasses, the percentage of Cu1+ and Cu0, combined, may be in the range from about 50% to about 99.9%, from about 50% to about 99%, from about 50% to about 95%, from about 50% to about 90%, from about 55% to about 99.9%, from about 60% to about 99.9%, from about 65% to about 99.9%, from about 70% to about 99.9%, from about 75% to about 99.9%, from about 80% to about 99.9%, from about 85% to about 99.9%, from about 90% to about 99.9%, from about 95% to about 99.9%, and all ranges and sub-ranges therebetween. The relative amounts of Cu1+, Cu2+, and Cu0 may be determined using x-ray photoluminescence spectroscopy (XPS) techniques known in the art.
Referring again to
In one or more embodiments of the antimicrobial floor coating 100, the durable phase of the phase-separable glass employed in the second phase particles is present in an amount by weight that is greater than the amount of the degradable phase. In some instances, the degradable phase forms islands and the durable phase forms the sea surrounding the islands (i.e., the durable phase). In one or more embodiments, either one or both of the durable phase and the degradable phase may include cuprite. The cuprite in such embodiments may be dispersed in the respective phase or in both phases.
In some embodiments of the phase-separable glass, phase separation occurs without any additional heat treatment of the glass. In some embodiments, phase separation may occur during melting and may be present when the glass composition is melted at temperatures up to and including about 1600° C. or 1650° C. When the glass is cooled, the phase separation is maintained (e.g., in a metastable state).
The phase-separable glass, as described in the foregoing, may be provided in sheet form or may have another shape such as particulate, fibrous, and the like. Referring to
The antimicrobial floor coating 100 according to one or more embodiments, and particularly its exterior surfaces 30 and 40 with exposed portions, may exhibit a 2 log reduction or greater (e.g., 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5 log, and all ranges and sub-ranges therebetween) in a concentration of at least one of Staphylococcus aureus, Enterobacter aerogenes, Pseudomonas aeruginosa, methicillin-resistant Staphylococcus aureus (MRSA), and E. coli bacteria under the modified United States Environmental Protection Agency “Test Method for Efficacy of Copper Alloy Surfaces as a Sanitizer” testing conditions, wherein the modified conditions include substitution of the antimicrobial floor coating with the copper-containing surface prescribed in the Method and use of copper metal article as the prescribed control sample in the Method (collectively, the “Modified EPA Copper Test Protocol”). As such, the United States Environmental Protection Agency “Test Method for Efficacy of Copper Alloy Surfaces as a Sanitizer” is hereby incorporated by reference in its entirety within the disclosure. In some instances, the antimicrobial floor coatings exhibit at least a 4 log reduction, a 5 log reduction, or even a 6 log reduction in the concentration of at least one of Staphylococcus aureus, Enterobacter aerogenes, Pseudomonas aeruginosa bacteria, MRSA, and E. coli under the Modified EPA Copper Test Protocol. Further, it should be noted that the degree of antimicrobial efficacy of the antimicrobial floor coating 100 can include the demonstration of a 2 log reduction in a concentration of Staphylococcus aureus (S. aureus), as determined under a test procedure derived from a protocol of the United States Environmental Protection Agency (the “Modified EPA Copper Test Protocol”). As S. aureus is one of the key bacteria against which a kill must be demonstrated by the Modified EPA Copper Test Protocol, a kill of S. aureus may be considered reasonable evidence of efficacy against a broad range of other bacteria (e.g., Eschecheria coli, Pseudomonas aeruginosa, and Enterobacter aerogenes), as understood by those with ordinary skill in the field of this disclosure.
The antimicrobial floor coating 100 according to one or more embodiments may exhibit the log reductions described herein for long periods of time. In other words, the antimicrobial floor coating 100 may exhibit extended or prolonged antimicrobial efficacy. For example, in some embodiments, the antimicrobial floor coating 100 may exhibit the log reductions described herein under the Modified EPA Copper Test Protocol for a week, two weeks, three weeks, up to 1 month, up to 3 months, up to 6 months, or up to 12 months after the antimicrobial floor coating 100 is formed.
According to one or more embodiments, the phase-separable glass, as employed as the controlled release agent of the second phase particle 20, may exhibit a preservative function, when combined with the matrix 10 described herein. In such embodiments, the phase-separable glass may kill or eliminate, or reduce the growth of various foulants in the matrix 10. Foulants include fungi, bacteria, viruses, and combinations thereof.
According to one or more embodiments, the antimicrobial floor coating 100 containing the phase-separable glasses described herein leach copper ions when exposed or in contact with a leachate. In one or more embodiments, the glass leaches only copper ions when exposed to leachates including water.
In one or more embodiments, the antimicrobial floor coating 100 described herein may have a tunable antimicrobial activity release. The antimicrobial activity of the phase-separable glass may be caused by contact between the second phase particles 20 containing the glass and a leachate, such as water, where the leachate causes Cu1+ ions to be released from the glass. This action may be described as water solubility and the water solubility can be tuned to control the release of the Cu+1 ions.
In some embodiments, where the Cu1+ ions are disposed in the glass network and/or form atomic bonds with the atoms in the glass network of the phase-separable glass, water or humidity breaks those bonds and the Cu1+ ions available for release and may be exposed on the second phase particles 20.
In one or more embodiments of the antimicrobial floor coating 100, the phase-separable glass may be formed in low cost melting tanks that are typically used for melting glass compositions such as soda lime silicate. Such phase-separable glass may be formed into a sheet form or directly into a particulate using forming processes known in the art. For instance, example forming methods include float glass processes and down-draw processes such as fusion draw and slot draw. When the phase-separable glass is formed into a sheet, it is subsequently ground or otherwise processed to form the second phase particles 20 employed in the antimicrobial floor coating 100.
As noted earlier, the antimicrobial floor coating 100 (see
According to some embodiments, the matrix 10 of the antimicrobial floor coating 100 (see
In one or more embodiments, the phase-separable glass may be provided in particulate form as second phase particles 20. In this form, the phase-separable glass may have a diameter in the range from about 0.1 micrometers (μm) to about 10 micrometers (μm), from about 0.1 micrometers (μm) to about 9 micrometers (μm), from about 0.1 micrometers (μm) to about 8 micrometers (μm), from about 0.1 micrometers (μm) to about 7 micrometers (μm), from about 0.1 micrometers (μm) to about 6 micrometers (μm), from about 0.5 micrometers (μm) to about 10 micrometers (μm), from about 0.75 micrometers (μm) to about 10 micrometers (μm), from about 1 micrometers (μm) to about 10 micrometers (μm), from about 2 micrometers (μm) to about 10 micrometers (μm), from about 3 micrometers (μm) to about 10 micrometers (μm) from about 3 micrometers (μm) to about 6 micrometers (μm), from about 3.5 micrometers (μm) to about 5.5 micrometers (μm), from about 4 micrometers (μm), to about 5 micrometers (μm), and all ranges and sub-ranges therebetween. The glass may be substantially spherical or may have an irregular shape.
The antimicrobial floor coatings 100 depicted in
In some embodiments, the antimicrobial floor coatings 100 described herein may include one or more fillers including pigments, that are typically metal based inorganics can also be added for color and other purposes, e.g., aluminum pigments, copper pigments, cobalt pigments, manganese pigments, iron pigments, titanium pigments, tin pigments, clay earth pigments (naturally formed iron oxides), carbon pigments, antimony pigments, barium pigments, and zinc pigments.
A further aspect of the present disclosure pertains to an antimicrobial floor coating formulation, which when dried and/or cured results in an antimicrobial floor coating 100 (see
In further implementations of this aspect, an exterior surface of the formulation upon drying of the aqueous medium, e.g., as an antimicrobial floor coating 100, exhibits at least a 2 log reduction in a concentration of Staphylococcus aureus under a Modified EPA Copper Test Protocol. Accordingly, the foregoing formulations can be dried and/or cured to form an antimicrobial floor coating 100, which exhibits the antimicrobial efficacy outlined earlier in the disclosure.
In further implementations of these floor coating formulations, used to form an antimicrobial floor coating 100, the epoxy, the acrylic polymer, and the aqueous medium are derived from a no-mix, one-part epoxy acrylic floor paint. These floor paints can include, according to some embodiments, Behr Premium® 1-Part Epoxy Concrete & Garage Floor Paint (from Behr Process Corporation), Drylock® E1 1-Part Epoxy Floor Paint (from United Gilsonite Laboratories), and Kilz® 1-Part Epoxy Acrylic Concrete & Garage Floor Paint (from Masterchem Industries LLC). Further, the epoxy of the formulation can be derived from an epoxy precursor that comprises one or more of dipropylene glycol monomethyl ether, dipropylene glycol butoxy ether, and ethylene glycol, the acrylic of the formulation can comprise a styrene acrylic polymer, and the matrix 10 of the formulation can further comprise nepheline syenite.
Referring to
As is evident from the results of
Referring now to
As is evident from the results of
Aspect (1) of this disclosure pertains to an antimicrobial floor coating, comprising: a matrix comprising a polymeric material; and a plurality of second phase particles comprising a controlled release agent, the controlled release agent comprising a plurality of antimicrobial copper ions, wherein the polymeric material comprises an epoxy and an acrylic, wherein the plurality of particles is distributed within the matrix, and further wherein an exterior surface of the coating exhibits at least a log 2 reduction in a concentration of Staphylococcus aureus under a Modified EPA Copper Test Protocol.
Aspect (2) of this disclosure pertains to the antimicrobial floor coating of Aspect (1), wherein the controlled release agent further comprises a phase-separable glass.
Aspect (3) of this disclosure pertains to the antimicrobial floor coating of Aspect (2), wherein an exterior surface of the coating exhibits at least a log 3 reduction in a concentration of Staphylococcus aureus under a Modified EPA Copper Test Protocol.
Aspect (4) of this disclosure pertains to the antimicrobial floor coating of any one of Aspects (2) or (3), further comprising one or more pigments.
Aspect (5) of this disclosure pertains to the antimicrobial floor coating of any one of Aspects (2) through (4), wherein the plurality of antimicrobial copper ions is at a concentration of about 2 wt. % or less in the coating.
Aspect (6) of this disclosure pertains to the antimicrobial floor coating of any one of Aspects (2) through (5), wherein the phase-separable glass comprises at least one of B2O3, P2O5 and R2O, and the plurality of antimicrobial ions is cuprite comprising a plurality of Cu′ ions.
Aspect (7) of this disclosure pertains to the antimicrobial floor coating of any one of Aspects (2) through (6), wherein the phase-separable glass comprises: SiO2 in the range from about 40 to about 70 mol %, Al2O3 in the range from about 0 to about 20 mol %, Cu-containing oxide in the range from about 10 to about 50 mol %, CaO in the range from about 0 to about 15 mol %, MgO in the range from about 0 to about 15 mol %, P2O5 in the range from about 0 to about 25 mol %, B2O3 in the range from about 0 to about 25 mol %, K2O in the range from about 0 to about 20 mol %, ZnO in the range from about 0 to about 5 mol %, Na2O in the range from about 0 to about 20 mol %, Fe2O3 in the range from about 0 to about 5 mol %, and an optional nucleating agent comprising either one or both of TiO2 and ZrO2, wherein the amount of the Cu-containing oxide is greater than the amount of Al2O3.
Aspect (8) of this disclosure pertains to the antimicrobial floor coating of any one of Aspects (2) through (7), wherein the polymeric material is derived from a no-mix, one-part epoxy acrylic floor paint.
Aspect (9) of this disclosure pertains to the antimicrobial floor coating of Aspect (8), wherein the phase-separable glass comprises: about 45 mol % SiO2, about 35 mol % CuO, about 7.5 mol % K2O, about 7.5 mol % B2O3 and about 5 mol % P2O5.
Aspect (10) of this disclosure pertains to the antimicrobial floor coating of Aspect (9), wherein the epoxy is derived from an epoxy precursor that comprises one or more of dipropylene glycol monomethyl ether, dipropylene glycol butoxy ether, and ethylene glycol, wherein the acrylic comprises a styrene acrylic polymer, and further wherein the matrix further comprises nepheline syenite.
Aspect (11) of this disclosure pertains to an antimicrobial floor coating formulation, comprising: an epoxy; an acrylic polymer; an aqueous medium; and a plurality of second phase particles comprising a controlled release agent, the controlled release agent comprising a plurality of antimicrobial copper ions, wherein the plurality of second phase particles is at a concentration that ranges from about 25 g/gallon to about 150 g/gallon of the formulation.
Aspect (12) of this disclosure pertains to the floor coating formulation according to Aspect (11), wherein the controlled release agent further comprises a phase-separable glass.
Aspect (13) of this disclosure pertains to the floor coating formulation according to Aspect (12), further comprising one or more pigments.
Aspect (14) of this disclosure pertains to the floor coating formulation according to Aspect (12) or (13), wherein the phase-separable glass comprises at least one of B2O3, P2O5 and R2O, and the plurality of antimicrobial copper ions is cuprite comprising a plurality of Cu+ ions.
Aspect (15) of this disclosure pertains to the floor coating formulation according to any one of Aspects (12) through (14), wherein the phase-separable glass comprises: SiO2 in the range from about 40 to about 70 mol %, Al2O3 in the range from about 0 to about 20 mol %, Cu-containing oxide in the range from about 10 to about 50 mol %, CaO in the range from about 0 to about 15 mol %, MgO in the range from about 0 to about 15 mol %, P2O5 in the range from about 0 to about 25 mol %, B2O3 in the range from about 0 to about 25 mol %, K2O in the range from about 0 to about 20 mol %, ZnO in the range from about 0 to about 5 mol %, Na2O in the range from about 0 to about 20 mol %, Fe2O3 in the range from about 0 to about 5 mol %, and an optional nucleating agent comprising either one or both of TiO2 and ZrO2, wherein the amount of the Cu-containing oxide is greater than the amount of Al2O3.
Aspect (16) of this disclosure pertains to the floor coating formulation according to any one of Aspects (12) through (15), wherein the epoxy, the acrylic polymer and the aqueous medium are derived from a no-mix, one-part epoxy acrylic floor paint.
Aspect (17) of this disclosure pertains to the floor coating formulation according to Aspect (16), wherein the phase-separable glass comprises: about 45 mol % SiO2, about 35 mol % CuO, about 7.5 mol % K2O, about 7.5 mol % B2O3 and about 5 mol % P2O5.
Aspect (18) of this disclosure pertains to the floor coating formulation according to Aspect (17), wherein the epoxy is derived from an epoxy precursor that comprises one or more of dipropylene glycol monomethyl ether, dipropylene glycol butoxy ether, and ethylene glycol, wherein the acrylic polymer comprises a styrene acrylic polymer, and further wherein the matrix comprises a nepheline syenite.
Aspect (19) of this disclosure pertains to the floor coating formulation according to any one of Aspects (12) through (18), wherein the plurality of second phase particles is at a concentration that ranges from about 50 g/gallon to about 125 g/gallon of the formulation.
Aspect (20) of this disclosure pertains to the floor coating formulation according to any one of Aspects (12) through (19), wherein an exterior surface of the formulation upon drying of the aqueous medium exhibits at least a log 2 reduction in a concentration of Staphylococcus aureus under a Modified EPA Copper Test Protocol.
It will be apparent to those skilled in the art that various modifications and variations can be made without departing from the spirit or scope of the invention.
This application claims the benefit of priority under 35 U.S.C. § 119 of U.S. Provisional Application Ser. No. 62/579,931 filed on Nov. 1, 2017, the content of which is relied upon and incorporated herein by reference in its entirety.
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/US2018/058383 | 10/31/2018 | WO | 00 |
Number | Date | Country | |
---|---|---|---|
62579931 | Nov 2017 | US |